Background: Ginsenosides are active natural compounds with diverse effects, and their interaction with the gut microbiota can influence microbial composition and abundance, though the long-term effects remain unclear. Methods: This study examines the impact of long-term oral ginsenoside administration on gut microbiota composition and structure in rats, as well as its pharmacokinetics. Twenty healthy male Wistar rats were divided into a control group (CK, receiving distilled water) and a ginsenoside treatment group (PGE, 100 mg/kg) for 30 days. Fecal samples were analyzed using 16S rRNA high-throughput sequencing on the Illumina HiSeq platform to assess microbial diversity. Concurrently, liquid chromatography–tandem mass spectrometry (LC-MS/MS) was utilized to determine the concentrations of ginsenosides in the serum and to investigate their pharmacokinetic properties (p < 0.05). Results: The results indicated that the α-diversity indices of the gut microbiota in the PGE group were significantly higher than in the CK group, suggesting that ginsenosides enhance microbial richness and diversity (p < 0.05). At the phylum level, the relative abundance of Firmicutes in the PGE group increased by 10.6% ± 2.72%, while that of Bacteroidetes decreased by 11.5% ± 3.18%; at the genus level, the proportion of Lactobacillus genus rose by 17.78% ± 4.37% (p < 0.05). Pharmacokinetic analysis revealed that the area under the concentration–time curve (AUC) and maximum concentration (Cmax) of ginsenosides were significantly higher in the PGE group than in the CK group. Conclusions: Chronic oral administration of ginsenosides improves their absorption and utilization through gut microbiota modulation, offering experimental evidence for deeper insight into ginsenoside–microbe interactions.
Dou et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: